Medpace Reference Laboratories LLC (MRL), a Medpace company, announced today that its new laboratories in Beijing, China and Mumbai, India have achieved accreditation by the College of American Pathologists (CAP), NGSP Level 1 and CDC Lipid Standardization (LSP) Part III. They complement laboratories in Leuven, Belgium and Cincinnati, USA with the same accreditations, providing MRL the ability to deliver consistent, identical, and highly standardized laboratory analysis to support clinical trials throughout the world. Accreditation by these internationally recognized programs reflect the high standards to which MRL is committed to achieve and maintain in order to best serve the pharmaceutical drug development process by seamlessly analyzing and incorporating safety and efficacy laboratory data across the globe.
The China and India facilities, like those in the USA and Europe, are wholly owned and operated in owned MRL state-of-the-art facilities which have been equipped with identical instrumentation, use the same reagent systems, calibration, QA and SOPs. All MRL laboratories are directly supervised by onsite, full-time doctoral level laboratory professionals including MDs and PhDs with training and board certification in Pathology/Laboratory Medicine.
"We believe that building a global network of identical and now fully accredited laboratories from scratch in only four years reflects the enormous experience, hard work and commitment to global excellence of our core team of laboratory professionals in the USA and Europe many of whom have worked together in clinical trials for nearly 20 years" said Evan Stein, MD PhD FCAP, FRCP (C), Chief Scientific Officer and Global Lab Director for MRL. "We are most appreciative of our pharmaceutical clients who made us the fastest start-up of any central laboratory and not only sustained but encouraged our rapid growth into these new regions."